What is Sacubitril-Valsartan ?

Sacubitril-Valsartan is a combination medication used to treat heart failure, particularly in patients with reduced ejection fraction, by enhancing the protective neurohormonal systems of the heart while inhibiting the detrimental effects of the renin-angiotensin-aldosterone system. Sacubitril acts as a neprilysin inhibitor, increasing levels of beneficial peptides, and Valsartan is an angiotensin II receptor blocker (ARB) that relaxes blood vessels, improving blood flow and reducing the heart's workload. This combination has been shown to significantly reduce the risk of cardiovascular death and hospitalizations related to heart failure.

• dizziness
• cough
• hyperkalemia
• renal impairment
• fatigue
• hypotension
• nausea

• Risk of angioedema, particularly in black patients and those with a history of angioedema.
• Potential for fetal toxicity; discontinue if pregnancy is detected.
• Do not use concomitantly with ACE inhibitors due to the risk of angioedema.
• Monitor serum potassium levels to manage the risk of hyperkalemia.
• Exercise caution in patients with renal artery stenosis or impaired renal function.
• Use carefully in patients with a history of hypotension or dehydration to avoid symptomatic hypotension.
• Avoid use in patients with severe hepatic impairment.